

Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2

Antonia Fernandez Ovale MD^a, Cassandra Charles BA^b, Janet Rosenbaum PhD^c, Priscila Villalba-Davila MD^a, Mauricio Mora MD^d, Shagun Sharma MBBS^e, Vivian Vega Lemus MD^e, Saema Khandakar MD^f, Thomas Wallach MD^e

Affiliations: ^a SUNY Downstate Health Sciences University, Department of Pediatrics; ^b SUNY Downstate Health Sciences University Research Foundation; ^c SUNY Downstate Health Sciences University, School of Public Health, Department of Biostatistics and Epidemiology; ^d Woodhull Hospital, Department of Pediatrics, ^e SUNY Downstate health Sciences University, Department of Pediatrics Division of Pediatric Gastroenterology; ^f Kings County Medical Center, Department of Pediatrics

Address correspondence to: Dr. Thomas Wallach, MD. 450 Clarkson Avenue Brooklyn, NY 11203 Ph: (718) 270-4714, Fax: (718) 270-8223, email: Thomas.wallach@downstate.edu

Short title: Age/Vaccination Decrease Pediatric SARS-CoV2 Hepatitis

Conflict of Interest Disclosures (includes financial disclosures): No conflicts of interest to disclose

Funding/Support: No funding was secured for this study.

Role of Funder/Sponsor (if any): No Funder/Sponsor.

Clinical Trial Registration (if any): N/A

Word Count: 2464

Figures and Tables: 4

Abbreviations: Aspartate Aminotransferase (AST), Alanine Aminotransferase (AST), Socioeconomic Status (SES),

Article Summary

Cross sectional study of an urban pediatric population demonstrates SARS-CoV2 transaminase elevation linked with younger age, unvaccinated status, and higher level of care.

1 **Abstract:**
2 **Objectives:** SARS-CoV2 infection is reported to induce transaminase elevations. There are case
3 reports of severe liver injury in adult SARS-CoV2 patients and some have theorized that acute
4 SARS-CoV2 infection may be a driver of severe liver injury in children. While pediatric hepatic
5 injury has previously been described, clear shifts in immunogenic response secondary to prior
6 immune exposure and vaccination since initial reports from 2020 warrant further evaluation. We
7 sought to identify the impact of variant shifts and vaccination on this phenomenon in children.
8 **Methods:** A retrospective, cross-sectional study of pediatric SARS-CoV2 patients seen at two
9 hospital facilities in an urban neighborhood in New York City between March 2020 and March
10 2022 was conducted via chart review. Data was extracted relating to patient's demographics,
11 clinical presentation, including the level of care and the laboratory results of comprehensive
12 metabolic panels (CMP).
13 **Results:** 133 pediatric cases were identified as having positive SARS-CoV2 and CMP obtained in
14 the same visit. Patients were predominantly Black (79.2%) and non-Hispanic (87%) with a mean
15 age of 9.2 years. Risk of transaminase elevation was increased in younger patients and patients
16 with higher level of care. BMI was not a risk factor noted for transaminase elevation. Vaccination
17 decreased degree, not incidence, of transaminase elevation but given low rates of vaccination
18 unable to determine significance of protective efficacy.
19 **Conclusions:** Our study has identified a profound increased risk of transaminase elevation in
20 younger patients, the absence of BMI as a correlating factor in our primarily Black patient
21 population, a shift towards non-specific AST elevation with variant windows and a strong signal
22 of vaccine protection.

23
24 **What is Known:**
25 • SARS-CoV2 can cause Transaminemia, and in rare cases, possible fulminant hepatic injury
26 • Pediatric SARS-CoV2 infections are statistically milder than adult.
27 • SARS-Cov2 case severity and complications like multisystem inflammatory syndrome in children
28 have declined over time

29 **What is New:**
30 • With population immunity and variant shifts transaminase elevations increasingly may not
31 be of hepatic origin
32 • Risk of transaminase elevation is substantially higher in younger patients, and decreases
33 with age
34 • Vaccines are protective against degree of transaminase elevation, and likely against
35 incidence of transaminase elevation, although further study is needed.

36
37
38
39
40
41
42
43
44
45
46

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71

Introduction

It has been well-documented since the onset of the pandemic that SARS-CoV2 infections can trigger elevations to serum transaminases, thus raising concerns for direct liver injury¹. While direct liver failure as a result of SARS-CoV2 appears to be rare and often perceived to be secondary to multi-organ injury in severely ill patients², it is not fully elucidated how acute viral infection impacts the pediatric liver nor how this picture has changed over time with evolved variants and acquired population immunity³. In 2021, a perceived cluster of pediatric fulminant liver failure led to rampant speculation that SARS-CoV2 was driving incidence, and raising concern for further increase. Further investigation led to foundational work demonstrating the role of adeno-associated virus but no evidence of SARS-CoV2 involvement was determined besides seroprevalence, which at that time was known to be wide^{4,5}.

In the adult population, it has been reported that approximately 20 to 30% of patients who were hospitalized due to SARS-CoV2 acute infection presented with acute liver injury (ALI), characteristically presenting with mild cholestasis and elevation of transaminases². While this rate may vary with disease severity and history of pre-existing conditions, it suggests that for adult patient's liver involvement may be predictive of more severe disease⁶, although it is unclear whether the impact on the liver was due to either severe illness or viral infection directly. Mechanistic work has suggested that direct viral injury to the liver is plausible⁷. Pediatric case series studies have suggested the viruses have the potential to drive liver failure⁸ yet further understanding of the natural history of this disease in pediatrics is needed, especially as meaningful interventions such as vaccination have been deployed.

72 As rates of fulminant liver injury have remained essentially unchanged over time, it is unlikely
73 that acute SARS-CoV2 infections have led to an increased need for liver transplantation or
74 frequently driven direct morbidity and mortality from hepatic injury. However, it remains a serious
75 possibility that SARS-CoV2 may present an ongoing risk for severe liver injury, especially given
76 evidence of increased capacity to drive autoimmunity, including liver specific disease⁹⁻¹¹. There is
77 an absence of confirmed findings for relatively rare events such as pediatric liver failure that is not
78 exculpatory of possible linkage. It is also likely that the pathology has shifted over time from
79 when previous studies of viral interaction with the pediatric liver^{12, 13} were reported which is
80 evidenced by overall decreasing clinical acuity and a rapid decline in Multisystem Inflammatory
81 Syndrome in Children (MIS-C) with different waves of variant infection¹⁴.

82
83 In this study, we sought to retrospectively assess the natural history, population immunity and
84 associated risks of acute lab-confirmed SARS-CoV2 infection on liver function at neighboring
85 hospital facilities in an urban neighborhood in Brooklyn, NY between March 2020 and March
86 2022. As SARS-CoV2 vaccination rates remain low in children, our work is particularly relevant
87 in understanding the value of vaccination in children which remains contentious and highly
88 important¹⁵. We hypothesized that transaminase elevations would be associated with increased
89 body mass index (BMI), a higher level of treatment care and more prevalent in the early phases of
90 the epidemic. We anticipated milder symptomology and lower rates of transaminase elevation in
91 those children improvement from prior immune exposure via infection or vaccination.

92

93

94

95 Methods

96 SUNY Downstate IRB and the Kings County STAR Committee approved the retrospective review
97 of the electronic medical records of pediatric patients evaluated for SARS-CoV2 at two
98 neighboring New York City institutions between March 2020 and March 2022. Our review
99 included all patients up to and including 18 years of age with confirmed SARS- CoV2 infection
100 via nasal swab- derived real- time reverse polymerase chain reaction, as well as a comprehensive
101 metabolic panel performed at the same visit. We reviewed over 3452 cases and identified 133
102 which met our criteria.

103
104 Clinical, demographic, laboratory and anthropometric data were collected. Patients were evaluated
105 at the emergency department prior to being admitted to the pediatrics floor or pediatric intensive
106 care unit. No patients were repeated. The following demographic covariates were extracted from
107 the patient chart: age in months, male versus female sex assigned at birth, Black vs non-Black race,
108 and Hispanic versus non-Hispanic ethnicity. We had the following health status measures: BMI,
109 preexisting conditions, and asthma status.

110
111 Patients that were diagnosed with MIS-C during the hospitalization were excluded. Patients with
112 sickle cell disease were also excluded from our analysis due to the possible increase of
113 transaminases due underlying hemolysis. All the patients included in our study that had a prior
114 value of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) available in
115 electronic medical record, had normal values for transaminases prior to the acute infection by
116 SARS-CoV-2. Patients with prior elevation of liver enzymes were excluded. AST and ALT
117 elevation were assigned using cutoffs from Bussler et al (AST >46, ALT >20)¹⁶. Transaminemia

118 trends were only followed up until discharge from the hospital. No follow up results were included
119 once patients were discharged from the unit.

120

121 Patients were categorized into two groups, one with elevated transaminases at initial encounter or
122 during hospitalization and another group that presented with normal transaminases at initial
123 encounter and during the hospital course, if admitted.

124

125 Gastrointestinal symptoms were considered positive if the patient presented with at least one of
126 the following: nausea, vomiting, diarrhea, abdominal pain and decrease oral intake. Obesity was
127 defined as body mass index (BMI) above 95th percentile and/or $BMI \geq 30 \text{ kg/m}^2$ as applicable.

128 Level of care was determined depending on the admission location or discharged from the
129 emergency department after initial encounter with no follow up.

130

131 SARS-CoV-2 variants were estimated variant type based on population sequencing data from New
132 York State. This was estimated by grouping patients on timelines according to the first time each
133 of the main variants was detected in New York until the time a subsequent variant was detected.

134 Vaccination status of each patient was reviewed as per city wide immunization records of New
135 York and the presence of SARS-CoV-2 antibody was accounted only when performed during the
136 acute SARS-CoV-2 infection hospitalization.

137

138

139

140

141 **Analysis**

142 We evaluated the association between elevated transaminases and continuous variables (age in
143 months, AST/ALT ratio, BMI z-score) using Kolgomorov-Smirnov to evaluate the difference
144 between the areas between the curves and the non-parametric Wilcoxon test. We used ggplot2 to
145 produce plots, <https://ggplot2.tidyverse.org>) in R 4.3.1¹⁷. Elevated transaminases were present in
146 53/133 patients. Multivariate Poisson regression was used to assess the outcome of elevated
147 transaminases in these patients.

148
149 Vaccination status is highly endogenous to age and date of presentation because the FDA issued
150 emergency use authorization for the vaccine approvals by age groups, and the vaccine was first
151 authorized for ages 12 and older on May 10, 2021 and for ages 5-11 on October 29, 2021, and the
152 vaccine was not available for under 5 until June 2022. In our sample, only 3 patients ages 5-11
153 were vaccinated. We cannot distinguish between the effects of older age and vaccination status.
154 SARS-CoV-2 antibody status was coded as true for children who tested positive on the antibody
155 test and coded negative for children who either were not administered an antibody test or who
156 tested negative on the antibody test: the test may have been differentially administered to children
157 who had elevated transaminases.

158
159 We used causal mediation analysis to evaluate how much of the association between vaccination
160 and elevated transaminases is mediated by age, using the mediation package¹⁸.

161

162

163

164 Results

165 133 patients meeting our criteria were included. Patients age was from 0 to 18 years old at the time
166 of encounter with a mean age of 9.2 years old. 52.9% of the patients were male and 45.5% of the
167 patients did not have a comorbidity. Most of our study population was black and non-Hispanic
168 with 79.2% and 87% respectively. No patients had progressive liver injury or evidence of liver
169 failure or complications of liver injury.

170
171 56% of patients presented with one or more gastrointestinal symptoms. 47.2% patients with
172 elevated transaminases presented with one or more gastrointestinal symptom at initial encounter.
173 There was no association between the presence of gastrointestinal symptoms and transaminase
174 elevation status (p-value = 0.20). There was also no statistical significance between vaccinated and
175 non-vaccinated patients and the presence of gastrointestinal symptoms at onset (p-value = 0.2).
176 There was no difference in BMI between patients that had elevated transaminases and the patients
177 that did not (p-value = 0.2).

178
179 Higher level of care was statistically associated with risk of transaminase elevation (p-value <
180 0.001). Patients with normal AST and ALT values were more likely to be seen in the ED and
181 subsequently discharged with 61% of the patients versus 32% of the patients that had elevated
182 transaminases.

183
184 In this patient population, 39.8% had elevated transaminases and 10.5% were vaccinated against
185 SARS-CoV2. Vaccinated children had lower AST: median 17.5 interquartile range (14.2, 28) vs
186 34.0 IQR (23.0, 52) (Figure 1). Among vaccinated children, the prevalence of transaminase

187 elevation was 21.4% and among unvaccinated children, the prevalence was 42.0%, but this
188 difference is not statistically significant. However, AST levels in unvaccinated patients were
189 significantly higher (34.0 vs 17.5, $p < 0.001$). There was no significant difference in mean ALT
190 level. (Table 1).

191

192 Younger children were more likely to have elevated transaminases $p = 0.0001$. Patients with normal
193 transaminase levels were on average 5 years older and more likely to be 5-11 and 12+ years old.
194 For each year of age, there were 7% fewer cases of transaminase elevation (PR = 0.93, 95% CI
195 (0.89, 0.97)). Patients older than 12 years old had 62% lower risk of elevated transaminases than
196 ages 0-11 years old. (Table 2) Rates of elevated transaminases appeared to increase by
197 predominant variant type, with 9/29 (31%) of wild type window patients, 3/10 (30%) of alpha
198 window patients, 9/23 (29.1%) delta window patients, and 32/71 (45.1%) for omicron window
199 patients. AST/ALT ratio increased during the omicron window.

200

201 Children who were vaccinated presented during the Omicron-prevalent period (since November
202 2021), were more likely to have preexisting conditions (79% vs. 44%) more likely to be 5 years
203 older at median (175 months vs. 102 months), and lower median AST/ALT ratio (1.4 vs. 1.9)
204 (Table 1). Vaccinated children had a higher mean BMI than never-vaccinated children (25.6 vs
205 21.3) (Table 1).

206

207 In causal mediation analysis, 51% of the effect of the effect of the vaccine on transaminase
208 elevation is mediated by a binary indicator for being age 12 or older, controlling for preexisting
209 condition and presenting during omicron ($p = 0.04$). In a second analysis, 69% of the effect of the

210 effect of the vaccine on transaminase elevation is mediated by age in months, controlling for
211 preexisting condition and presenting during omicron ($p=0.02$). However, the percentage of the
212 effect of the effect of the vaccine on transaminase elevation is mediated by age in months
213 controlling for preexisting condition and BMI class is not statistically significant ($p=0.08$).

214

215 Discussion

216 While other studies have in part characterized the impact of SARS-CoV2 on the pediatric liver,
217 this is the first reported work we are aware of to assess alterations to this behavior over variant
218 windows, the first to assess vaccine protection, and the first to review this in a population of
219 majority african descent and a correspondingly low risk of NAFLD. A focus on a minoritized and
220 low-income population is also highly relevant, as this population remains most at risk of SARS-
221 CoV2 infection¹⁹. We note: a significant age association (higher risk in younger children), a shift
222 in characteristic of transaminase elevation over the variant windows, an absence of a BMI
223 association in this primarily Black cohort, and a significant difference in AST elevation and likely
224 difference in overall risk of transaminase elevation in vaccinated patients. Our most significant
225 finding is the likely protective effect of vaccination, although due to the timing of our data and the
226 strong age association of transaminase elevation risk, we were not able to determine significance
227 in this study despite a wide practical variation and severity range between vaccinated and
228 unvaccinated patients.

229 We have noted that pediatric patients with elevated transaminases were more likely to require
230 higher level of care, although in the absence of a prospective study examining serial measurements
231 and outcomes it is not clear if this reflects a risk factor or an outcome of severe illness.

232 Interestingly, BMI, which has been felt to be a major risk factor both for SARS-CoV2 severity and
233 transaminase elevation secondary to non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty
234 liver disease (NAFLD) ^{20, 21}, was not relevant, displaying no increased risk of transaminase
235 elevation. However, as our hospital center serves a patient population with atypical demographics
236 (see high percentage of Black race in demographics) this may be an outlier reflecting a specific
237 resistance to NASH/NAFLD due to polymorphisms such as PNPLA-3 or MBOAT7²².

238 Interestingly, children that were vaccinated presented with less incidence of elevated
239 transaminases than non-vaccinated children (42 versus 21%, p-value 0.2%), although it was not
240 statistically significant due to previously discussed limitation on the age range of vaccinated
241 patients, and the strong correlation of young age and elevated transaminases. Level of
242 transaminase elevation was significantly lower in vaccinated patients (AST 17.5 vs. 34.0, p =
243 0.002) suggesting a degree of protective impact. This is likely a function of age/limitations on
244 when vaccines were available in young children, and it seems highly likely that in a larger study a
245 strong vaccine protection would be noted.

246 Our study returned other notable findings. First, while we had theorized that GI infection may
247 predispose to transaminase elevation, no connection was noted (Table 2). Second, we observed
248 that with variant progression and population immunity levels there were shifts to the AST/ALT
249 ratio (The DeRitis ratio) The ratio represents the time course and aggressiveness of disease that
250 would be predicted from the relatively short half-life of AST (18 h) compared to ALT (36 h), and
251 can be used to infer origin of transaminase elevation²³. As the AST/ALT ratio increased over the
252 time (Figure 2), it may be that transaminase elevations are increasingly of extra hepatic origin.

253 Acute illness can also increase AST due to his extra hepatic presence in the muscle, heart and
254 kidney, which aligns with our finding that level of care was linked to transaminase elevation.

255 In summary, this retrospective cross-sectional study of SARS-CoV2 associated hepatic injury and
256 transaminase elevation has clearly identified major risk factors of young age and disease severity,
257 and highly suggests a strong protective effect from vaccination. It also suggests that increasingly
258 transaminase elevation in this population may not be primarily hepatic, although further study is
259 needed. This study was limited by its retrospective nature, lack of reliably trended results, the bias
260 towards severity inherent in requiring lab work (as frequently mild infections do not result in serum
261 testing), and population size. With that said, several patients had transaminase elevations of
262 significant size, suggesting risk in rare cases for fulminant hepatitis. This work presents a further
263 argument towards the value of pediatric vaccination, although additional larger studies are
264 indicated.

265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284

References:

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
2. Sobotka LA, Esteban J, Volk ML, et al. Acute Liver Injury in Patients Hospitalized with COVID-19. *Dig Dis Sci* 2022;67:4204-4214.
3. Li P, Liu Y, Cheng Z, et al. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. *Biomed Pharmacother* 2022;154:113568.
4. Jones JM, Manrique IM, Stone MS, et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022. *MMWR Morb Mortal Wkly Rep* 2023;72:601-605.
5. Lewis L, van Wylick C, Mulder DJ. A systematic review of the proposed etiologies of the 2021-2022 outbreaks of pediatric acute hepatitis of unknown etiology. *Front Pediatr* 2023;11:1285348.
6. Wang M, Wu D, Liu CH, et al. Predicting progression to severe COVID-19 using the PAINT score. *BMC Infect Dis* 2022;22:498.
7. Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. *Protein Cell*. Volume 11, 2020:771-775.
8. Antala S, Diamond T, Kociolek LK, et al. Severe Hepatitis in Pediatric Coronavirus Disease 2019. *J Pediatr Gastroenterol Nutr* 2022;74:631-635.
9. Rosenbaum J, Ochoa KC, Hasan F, et al. Epidemiologic Assessment of Pediatric Inflammatory Bowel Disease Presentation in NYC During COVID-19. *medRxiv* 2022:2022.03.23.22272167.
10. Saad MA, Alfshawy M, Nassar M, et al. COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases. *Curr Rheumatol Rev* 2021;17:193-204.
11. Terebuh P, Olaker VR, Kendall EK, et al. Liver abnormalities following SARS-CoV-2 infection in children 1 to 10 years of age. *Family Medicine and Community Health* 2024;12:e002655.
12. Sumner MW, Florin TA, Kuppermann N, et al. Liver transaminase concentrations in children with acute SARS-CoV-2 infection. *Clinical Biochemistry* 2023;118:110588.
13. Perez A, Cantor A, Rudolph B, et al. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. *Liver Int* 2021;41:2068-2075.
14. Eleftheriou I, Maritsi D, Lampidi S, et al. Decreasing Incidence of the Multisystem Inflammatory Syndrome in Children Over 3 Pandemic Waves. *Pediatr Infect Dis J* 2023;42:122-124.
15. Brodin P. Immune responses to SARS-CoV-2 infection and vaccination in children. *Semin Immunol* 2023;69:101794.
16. Bussler S, Vogel M, Pietzner D, et al. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ -glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage. *Hepatology* 2018;68:1319-1330.
17. Wickham H. *ggplot2: Elegant Graphics for Data Analysis (Use R)*. Springer-Verlag 2016.



18. Tingley D, Yamamoto T, Hirose K, et al. mediation: R Package for Causal Mediation Analysis. *Journal of Statistical Software* 2014;59:1 - 38.
19. Sahli S, Størdal K. Systematic review of socioeconomic factors and COVID-19 in children and adolescents. *Acta Paediatr* 2024.
20. Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. *Gastroenterology* 2010;138:1357-64, 1364.e1-2.
21. Ohno M, Džúrová D. Body Mass Index and Risk for COVID-19-Related Hospitalization in Adults Aged 50 and Older in Europe. *Nutrients* 2022;14.
22. Bonacini M, Kassamali F, Kari S, et al. Racial differences in prevalence and severity of non-alcoholic fatty liver disease. *World J Hepatol* 2021;13:763-773.
23. Botros M, Sikaris KA. The de ritis ratio: the test of time. *Clin Biochem Rev* 2013;34:117-30.

Table 1: Demographics and Biomarkers at Time of Presentation by Vaccination Status

Table 2: Demographics and Results by Transaminase Elevation Status

Figure 1: Violin Plot Summary of a) AST and b) ALT elevation by vaccination status.

Figure 2: Change in Transaminase Elevation Behavior by Variant Window. A) AST/ALT ratio by window. B) ALT log scale by window. C) AST log scale by window.



medRxiv preprint doi: <https://doi.org/10.1101/2024.04.01.24303996>; this version posted April 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Table 1: Demographics and biomarkers at time of presentation by vaccination status

	No vaccine (n=119)	Vaccine (n=14)	P-value
Transaminemia	50 (42.0%)	3 (21.4%)	0.2
AST (highest), median, IQR	34.0 (23.0, 52)	17.5 (14.2, 28)	<0.001
AST elevations			0.2
None [Normal AST ≤ 46]	85 (71.4)	14 (100)	
Mild [Abnormal, less than 2x ULN]	29 (24.4)	0	
Moderate [Between 2-5x ULN]	4 (3.4)	0	
Severe [More than 5x ULN]	1 (0.8)	0	
AST/ALT ratio, median, IQR	1.90 (1.36, 2.54)	1.40 (1.06, 1.85)	0.02
ALT, median, IQR	17.0 (12.0, 22.5)	14.5 (10.8, 18.5)	0.2
Random glucose, median, IQR	97.0 (89.0, 107.0)	96.0 (88.0, 121.5)	0.9
Albumin, median, IQR	4.50 (4.1, 4.8)	4.35 (4.1, 4.8)	0.8
Alkaline phosphatase, median, IQR	208 (113, 258)	117.5 (60.8, 220)	0.1
Platelets, median, IQR	267 (207, 368)	298.5 (235.8, 362.3)	0.5
Total bilirubin, median, IQR	0.40 (0.2, 0.6)	0.40 (0.2, 0.6)	0.8
Age (months), median (interquartile range) (range)	108 (26, 180) (Range: 1-216)	186 (156, 204) (Range: 84-223)	0.001
Age group			0.007
0-4 years	34 (28.6%)	0	
5-11 years	40 (33.6%)	3 (21.4%)	
12-19 years	45 (37.8%)	11 (78.6%)	
Hospital			0.03
Downstate	32 (26.9%)	8 (57.1%)	
Kings County	87 (73.1%)	6 (42.9%)	
Date presenting			0.003
Mar.-Dec. 2020	29 (24.4%)	0	
Jan.-June 2021	10 (8.4%)	0	
June-Nov. 2021	23 (19.3%)	0	
Nov. 2021-Mar. 2022	57 (47.9%)	14 (100%)	
Black race	90 (78.3%)	12 (85.7%)	0.7
Non-Hispanic ethnicity	105 (91.3%)	13 (92.9%)	1.0
Male sex	63 (52.9%)	9 (64.3%)	0.4
Preexisting conditions	52 (43.7%)	11 (78.6%)	0.01
Asthma	16 (13.4)	6 (42.9)	0.01
BMI, median, IQR	19.2 (16.8-24.5)	25.6 (19.0, 27.0)	0.02
BMI z-score, median (IQR)	0.47 (-0.40, 1.67)	1.21 (0.24, 1.81)	0.2
BMI z-score, mean (SD)	0.41 (1.75)	1.02 (1.25)	0.1

BMI class			0.2
0	68 (62.4%)	6 (42.9%)	
1	20 (18.3%)	3 (21.4%)	
2	21 (19.3%)	5 (35.7%)	
Missing	10 (8.4%)	0	
Presenting with GI symptoms	63 (52.9)	10 (71.4)	0.2
Presenting with nausea	31 (26.1)	3 (21.4)	1.0
Presenting with diarrhea	14 (11.8)	2 (14.3)	0.7
Presenting with decreased intake	18 (15.1)	1 (7.1)	0.7
Presenting with abdominal pain	22 (18.5)	5 (35.7)	0.2
Presenting with other GI symptoms	22 (18.5)	4 (28.6)	0.5
Level of care			0.3
ED and discharged	56 (47.1)	10 (71.4)	
Floor	45 (37.8)	3 (21.4)	
PICU	18 (15.1)	1 (7.1)	

P-value for continuous variables was from Wilcoxon test due to skewed distributions. P-value from categorical variable was from chi-square test.

Table 2: Demographics by transaminase elevation status

	No elevated transaminases (n=80)	Elevated transaminases (n=53)	P-value
Vaccinated	11 (13.8%)	3 (5.7%)	0.1
Antibody positive (vs. no testing or negative)	23 (31.9)	6 (12.2)	0.01
AST, median, IQR	24 (18, 33) Range 12-46	56 (42, 72) Range (12-1137)	<0.001
AST elevations			
None [Normal AST ≤ 46]	80 (100)	19 (35.8)	
Mild [Abnormal, less than 2x ULN]	0	29 (54.7)	
Moderate [Between 2-5x ULN]	0	4 (7.5)	
Severe [More than 5x ULN]	0	1 (1.9)	
AST/ALT ratio, median, IQR	1.9 (1.5, 2.3) Range 0.6-8.40	2.1 (1.1, 3.2) Range 0.32-6.31	0.8
ALT, median, IQR	13.5 (11.0, 17.0)	27.0 (18.0, 41.0)	<0.001
Glucose, median, IQR	96.0 (89.0, 109.0)	98.0 (88.0, 107.0)	0.9
Albumin, median, IQR	4.55 (4.2, 4.8)	4.50 (3.9, 4.8)	0.6
Alkaline Phosphatase, median, IQR	181 (84.8, 241)	225 (133, 269)	0.05
Platelets, median, IQR	279 (217, 374)	270 (197.5, 352.5)	0.4
Total bilirubin	0.4 (0.2, 0.5)	0.4 (0.2, 0.7)	0.2
Age (months), median (interquartile range) (range)	144 (69, 201) Range 1-216	60 (13, 144) Range 1-223	<0.001
Age group			0.002
0-4 years	13 (16.2%)	21 (39.6%)	
5-11 years	25 (31.2%)	18 (34.0%)	
12-19 years	42 (52.5%)	14 (26.4%)	
Hospital			0.98
Downstate	24 (30.0%)	16 (30.2%)	
Kings County	56 (70.0%)	37 (69.8%)	
Date presenting			0.55
Mar.-Dec. 2020	20 (25.0%)	9 (17.0%)	
Jan.-June 2021	7 (8.8%)	3 (5.7%)	
June-Nov. 2021	14 (17.5%)	9 (17.0%)	
Nov. 2021-Mar. 2022	39 (48.8%)	32 (60.4%)	
Black race	61 (79.2%)	41 (78.8%)	0.96
Hispanic ethnicity	6 (7.8%)	5 (9.6%)	0.76
Male sex	37 (46.2%)	35 (66%)	0.02
Preexisting conditions	38 (47.5%)	25 (47.2%)	0.97
Asthma	19 (23.8)	3 (5.7)	0.006
BMI, median, IQR	20.0 (17.7, 26.0)	18.7 (16.5, 24.7)	0.2
BMI z-score, median (IQR)	0.56 (-0.41, 1.79)	0.79 (-0.22, 1.41)	1

BMI class			0.3
0	44 (55.0%)	30 (56.6%)	
1	12 (15.0%)	11 (20.8%)	
2	19 (23.8%)	7 (13.2%)	
Missing	5 (6.3%)	5 (9.4%)	
Presenting with GI symptoms	48 (60.0)	25 (47.2)	0.2
Presenting with nausea	19 (23.8)	15 (28.3)	0.6
Presenting with diarrhea	10 (12.5)	6 (11.3)	0.8
Presenting with diminished food intake	15 (18.8)	4 (7.5)	0.07
Presenting with other GI symptoms	20 (25.0)	6 (11.3)	0.05
Level of care			0.001
ED and discharged	49 (61.3%)	17 (32.1%)	
Floor	25 (31.2%)	23 (43.4%)	
PICU	6 (7.5%)	13 (24.5%)	

P-value for continuous variables was from Wilcoxon test due to skewed distributions. P-value from categorical variable was from chi-square test.